Showing results (161-170 of 422) with videos related to

Sort By:
Pageof 43
Biorxiv : the Preprint Server for Biology|December 15, 2025
Crystallographic Ensembles Reveal the Structural Basis of Binding Entropy in SARS-CoV2 MacrodomainLouella Seo, Ian Farran, Ahmed Aslam, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Association of genetic variants at 8q24 with breast cancer riskOlivia Fletcher, Nichola Johnson, Lorna Gibson, et al.
Cancer Research|May 16, 2015
Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast CancerAlina Lemnrau, Mark N Brook, Olivia Fletcher, et al.
Cancer Discovery|May 26, 2012
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1Marieke Aarts, Rachel Sharpe, Isaac Garcia-Murillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2013
Noninvasive detection of HER2 amplification with plasma DNA digital PCRHeidrun Gevensleben, Isaac Garcia-Murillas, Monika K Graeser, et al.
Plos Genetics|September 28, 2011
Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in menNick Orr, Rosie Cooke, Michael Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiencyYuqiao Shen, Farah L Rehman, Ying Feng, et al.
British Journal of Cancer|July 29, 2016
Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?Michael E Jones, Minouk J Schoemaker, Lauren Wright, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Nature|February 12, 2008
Resistance to therapy caused by intragenic deletion in BRCA2Stacey L Edwards, Rachel Brough, Christopher J Lord, et al.
Pageof 43